Zenith Drugs — 360° view

Zenith Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹93 crore and net profit of ₹2.00 crore for the March 2026 quarter.

Zenith Drugs (NSE: ZENITHDRUG-SM) closed at ₹40.00 on 20 Nov 2026, down 31.7% over the past year. Its market capitalisation is ₹69 crore and it trades at 16.7 times earnings.

Share price
₹40.00 (20 Nov 2026)
Market cap
₹69 Cr (20 Nov 2026)
P/E
16.69 (20 Nov 2026)
Revenue
₹93 Cr (March 2026 quarter)
Net profit
₹2 Cr (March 2026 quarter)
ROCE
9.08% (FY26)
ROE
5.76% (FY26)
Book value
₹42.8 (FY26)
Dividend yield
0.00% (last 12 months to 20 Nov 2026)
52-week high / low
₹58.05 / ₹33.30 (20 Nov 2026)
1-year return
-31.7% (to 20 Nov 2026)
Sector
Healthcare
Industry
Pharmaceuticals
Symbol
NSE: ZENITHDRUG-SM

Incorporated in 2000, Zenith Drugs Ltd is manufacturer of a range of healthcare drugs and allied products

Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.